Log in
Enquire now
‌

US Patent 10150797 Respiratory syncytial virus (RSV) vaccine

Patent 10150797 was granted and assigned to CureVac on December, 2018 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors
Is a
Patent
Patent
Current Assignee
CureVac
CureVac
Date Filed
April 17, 2017
Date of Patent
December 11, 2018
Patent Applicant
CureVac
CureVac
Patent Application Number
15488815
Patent Citations Received
‌
US Patent 12109275 Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded protein
0
‌
US Patent 11760992 Method for producing and purifying RNA, comprising at least one step of tangential flow filtration
‌
US Patent 11761009 Artificial nucleic acid molecules for improved protein expression
‌
US Patent 11786590 Rotavirus vaccines
‌
US Patent 11834651 Method for producing and purifying RNA, comprising at least one step of tangential flow filtration
0
‌
US Patent 11865084 MERS coronavirus vaccine
0
‌
US Patent 11965000 Respiratory syncytial virus (RSV) vaccine
0
‌
US Patent 12083190 Rabies vaccine
0
‌
US Patent 10869935 RNA containing composition for treatment of tumor diseases
0
‌
US Patent 10918740 RNA containing composition for treatment of tumor diseases
0
•••
Patent Inventor Names
Benjamin Petsch
0
Margit Schnee
0
Thomas Kramps
0
Daniel Voss
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
10150797
Patent Primary Examiner
‌
Janet L. Andres

Find more entities like US Patent 10150797 Respiratory syncytial virus (RSV) vaccine

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.